The sensation of satiety is one of the most noted effects reported by patients on tirzepatide. This profound reduction in appetite is not a mere suppression of hunger: it results from a complex reprogramming of the neuronal, hormonal, and mechanical signals that control our eating behavior.
The Three Levels of Appetite Control
Appetite control is organized into three hierarchical levels that tirzepatide influences simultaneously:
1. The Mechanical Signal (Stomach)
Tirzepatide significantly slows gastric emptying via its GLP-1 action. Food remains in the stomach longer, activating gastric mechanoreceptors that transmit distension signals to the brain via the vagus nerve. This slowing is dose-dependent: it is maximal in the first weeks of treatment, then partially attenuates (partial tolerance), which explains the gradual decrease in nausea.
2. The Hormonal Signal (Gut-Brain)
Activation of GLP-1 and GIP receptors in the central nervous system directly modifies hunger and satiety signals:
- GLP-1 activates POMC (pro-opiomelanocortin) neurons in the arcuate nucleus of the hypothalamus, which produce an anorexigenic (appetite-suppressing) signal.
- It simultaneously inhibits NPY/AgRP neurons that normally stimulate hunger.
- GIP activates complementary neurons in the lateral hypothalamus, reducing food motivation.
- Both hormones modulate the dopaminergic reward circuit in the nucleus accumbens.
3. The Metabolic Signal (Adipose Tissue-Brain)
As fat mass decreases, leptin levels (the satiety hormone produced by adipose tissue) should normally drop, stimulating hunger and promoting weight regain. Tirzepatide partially counteracts this effect by maintaining strong central activation of GIP and GLP-1 receptors, independent of leptin levels.
What Patients Experience in Practice
Qualitative studies conducted with participants in the SURMOUNT trials report several subjective changes:
- Reduced appetite between meals: 78% of patients describe a significant decrease in hunger between meals from the first weeks (Garvey et al., Obesity, 2023).
- Faster satiety: patients report feeling full with smaller portions, often 30 to 50% less than their usual portions.
- Change in food preferences: decreased craving for fatty, sugary, and ultra-processed foods. This phenomenon, called « food noise reduction », is one of the most commonly reported effects.
- Disappearance of compulsive cravings: many patients describe the disappearance of impulsive snacking episodes and irresistible urges.
- Relative disinterest in food: some patients report « forgetting to eat » or no longer thinking about food obsessively.
The Concept of « food noise »
The term « food noise » has become popular to describe the experience of patients on incretin agonists. It refers to intrusive and repetitive thoughts related to food: « What am I going to eat? », « I want chocolate, » « When is the next meal? ».
Activation of GIP and GLP-1 receptors in brain areas of the reward circuit (nucleus accumbens, prefrontal cortex, amygdala) reduces this compulsive mental activity. Functional brain imaging studies (fMRI) have shown that tirzepatide reduces activation of the prefrontal cortex and amygdala in response to images of appetizing foods (Schneider et al., Diabetes Care, 2024).
Timeline of Appetite Effects
| Period | Typical Dose | Appetite Effects |
|---|---|---|
| Week 1-4 | 2.5 mg | Initial appetite reduction. Early satiety. Possible nausea. |
| Week 5-8 | 5 mg | Marked appetite reduction. Portions naturally reduced by 30%. Decrease in food noise. |
| Week 9-16 | 7.5-10 mg | Stable effect on satiety. Nausea generally resolved. Change in food preferences. |
| Week 17-24 | 12.5-15 mg | Maximal effect. Some patients need to force themselves to eat enough. |
| Month 6+ | Maintenance Dose | Plateau. Appetite stabilizes at a reduced but functional level. |
Differences from Traditional Appetite Suppressants
Older appetite suppressants (phentermine, sibutramine, fenfluramine) primarily acted on monoaminergic neurotransmitters (serotonin, norepinephrine, dopamine), with significant cardiovascular and psychiatric effects. Tirzepatide stands out due to:
- Physiological mechanism: it amplifies natural satiety signals (incretins), rather than creating an artificial state of hunger suppression.
- Absence of stimulant effect: no tachycardia, no insomnia, no risk of dependence.
- Peripheral and central action: it acts on the stomach, intestines, pancreas, and brain, creating a multilevel satiety signal.
- Additional metabolic effects: improvement in blood glucose, lipid profile, and blood pressure, well beyond simple appetite suppression.
Risks of Excessively Reduced Appetite
Extreme appetite reduction can sometimes become problematic:
- Insufficient protein intake: the main risk is too low protein consumption, accelerating muscle mass loss. The goal is to maintain at least 1.2 g of protein per kg of ideal body weight per day.
- Dehydration: reduced appetite is often accompanied by reduced thirst. It is essential to maintain a fluid intake of 1.5 to 2 liters per day.
- Vitamin deficiencies: reduced portions can lead to deficiencies in iron, vitamin B12, vitamin D, and calcium if the diet is not qualitatively optimized.
- Eating disorders: in predisposed patients, extreme appetite reduction can unmask or worsen restrictive eating disorders. Psychological follow-up is recommended.
Optimizing Satiety Without Suffering
Several strategies can maximize the benefits of satiety while maintaining adequate nutrition:
- Prioritize proteins at the start of meals: beginning with proteins ensures sufficient intake even if portions are reduced.
- Split meals: 5-6 small meals per day rather than 3 large ones, to maintain total caloric intake.
- Drink between meals: separate hydration from meals to avoid filling the stomach with water at the expense of nutrients.
- Choose nutrient-dense foods: prefer foods with high nutritional density (eggs, fish, legumes) rather than bulky but less nutritious foods.
- Supplement if necessary: a multivitamin supplement and a protein supplement can be useful during high-dose phases.
FAQ
How long does appetite loss last with tirzepatide?
Appetite reduction persists as long as treatment is continued. It reaches its maximum between week 16 and 24 (target dose), then stabilizes. Upon discontinuation of treatment, appetite gradually returns within 2 to 6 weeks.
Is it normal to have no hunger at all?
A marked reduction in appetite is normal and expected, especially during the titration phase. However, a total loss of appetite for more than 48 hours, accompanied by persistent nausea, warrants medical consultation and possibly a dose adjustment.
Is tirzepatide an appetite suppressant?
It is not a classic appetite suppressant. Tirzepatide acts by amplifying natural satiety signals (incretin hormones) rather than artificially suppressing hunger. Its mechanism is physiological and does not involve sympathetic nervous system stimulation.
What if I can’t eat enough?
Prioritize proteins and nutrient-dense foods. Split your meals into 5-6 small servings. If appetite loss is excessive, your doctor may consider a temporary return to a lower dose.
Does food noise return after stopping treatment?
Yes, most patients report a gradual return of food noise in the weeks following discontinuation. This is one reason why long-term treatment maintenance or complementary behavioral strategies are recommended.
Sources
- Garvey WT et al. Patient-reported outcomes with tirzepatide in the SURMOUNT program. Obesity. 2023.
- Schneider E et al. Brain responses to food cues under GLP-1 receptor agonism. Diabetes Care. 2024.
- Muller TD et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201-223.
- Van Can J et al. Reduced GLP-1 secretion at the meal level in type 2 diabetes. Diabetologia. 2014;57:2150-2158.
- Nauck MA, Muller TD. Incretin hormones and type 2 diabetes. Diabetologia. 2023;66:1780-1795.